Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Tonix Pharmaceuticals prices $10.5M common stock offering » 13:38
07/13/20
07/13
13:38
07/13/20
13:38
TNXP

Tonix Pharmaceuticals

$0.55 /

-0.0925 (-14.50%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 20,940,000 shares of common stock, par value $0.001 per share at an offering price of $0.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $10.5M before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about July 15, 2020, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.55 /

-0.0925 (-14.50%)

TNXP Tonix Pharmaceuticals
$0.55 /

-0.0925 (-14.50%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.55 /

-0.0925 (-14.50%)

  • 16
    Jul
TNXP Tonix Pharmaceuticals
$0.55 /

-0.0925 (-14.50%)

Hot Stocks
Tonix enters research, license agreement with Kansas State University » 07:14
07/13/20
07/13
07:14
07/13/20
07:14
TNXP

Tonix Pharmaceuticals

$0.64 /

-0.0208 (-3.16%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced a new preclinical research and option agreement with Kansas State University to develop a vaccine candidate for the prevention of COVID-19 that utilizes a novel live virus vaccine vector platform and the CD40-ligand, also known as CD154 or 5c8 antigen, to stimulate T cell immunity. Under the research agreement, K-State will advance preclinical development of a live replicating virus vaccine to protect against COVID-19 based on bovine parainfluenza virus. Attenuated bovine parainfluenza virus has previously been shown to be an effective antigen delivery vector in humans1-6. Notably and most importantly, following extensive testing in non-human primates, the attenuated BPI3V was shown to be well tolerated, infectious, immunogenic, and stable in infants and children2, 5. The vector is well suited for mucosal immunization using a nasal atomizer, but it can also be delivered parenterally. The technology also includes a molecular stimulant called CD40-ligand, which triggers strong immunity including T cell responses. The vaccine is designed to potentially stimulate immunity against the SARS-CoV-2 spike protein. The research will be directed by Dr. Waithaka Mwangi, Kansas State University, Department of Diagnostic Medicine/Pathobiology, who is the inventor of the new technology. In addition, K-State has granted Tonix an option for an exclusive license for the clinical and commercial use of K-State's intellectual property associated with coronavirus vaccines under this relationship.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0208 (-3.16%)

TNXP Tonix Pharmaceuticals
$0.64 /

-0.0208 (-3.16%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0208 (-3.16%)

  • 16
    Jul
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0208 (-3.16%)

Over a week ago
Hot Stocks
Tonix Pharmaceuticals announces intent to purchase Massachusetts R&D facility » 07:15
07/07/20
07/07
07:15
07/07/20
07:15
TNXP

Tonix Pharmaceuticals

$0.59 /

-0.01 (-1.67%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in Massachusetts to use as laboratories to enable R&D functions associated with its portfolio of immunology candidates, including vaccines for COVID-19 and biological products for other disorders.Tonix's advanced development center is expected to expand the company's capabilities in process and analytical development. Tonix will continue working collaboratively in certain cases with outside partners, such as its current collaborations with Southern Research for preclinical testing and with FujiFilm Diosynth Biotechnologies for the manufacturing of the TNX-801 and TNX-1800 vaccines for smallpox and COVID-19, respectively. Both vaccines utilize Tonix's proprietary live replicating virus platform, which is designed to potentially elicit a predominately T cell response, believed to be essential in conferring long-term vs. temporary immunity. Preclinical results from the TNX-1800 COVID-19 study in small animals and non-human primates are expected in Q4. The R&D facility is expected to be operational in 2022.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.59 /

-0.01 (-1.67%)

TNXP Tonix Pharmaceuticals
$0.59 /

-0.01 (-1.67%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.59 /

-0.01 (-1.67%)

  • 16
    Jul
TNXP Tonix Pharmaceuticals
$0.59 /

-0.01 (-1.67%)

Hot Stocks
Tonix says enrollment in Phase 3 RELIEF trial 'ahead of schedule' » 07:11
06/29/20
06/29
07:11
06/29/20
07:11
TNXP

Tonix Pharmaceuticals

$0.60 /

+0.0173 (+2.95%)

Tonix announced that due…

Tonix announced that due to faster-than-expected enrollment, the Company anticipates topline Phase 3 RELIEF results in the fourth quarter of 2020, rather than the first quarter of 2021 as previously guided. RELIEF is a potential pivotal study of TNX-102 SL 5.6 mg, a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. An optional interim analysis of the first 50 percent of randomized participants that are evaluable for efficacy will be conducted, with results expected in September 2020. The RELIEF study is a double-blind, randomized, placebo-controlled adaptive design trial designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg in fibromyalgia. The trial is expected to enroll approximately 470 participants across approximately 40 U.S. sites. For the first two weeks of treatment, there is a run-in period in which participants start on TNX-102 SL 2.8 mg or placebo. After the first two weeks, all participants have the dose increased to TNX-102 SL 5.6 mg or two placebo tablets for 12 weeks. The primary endpoint is daily diary pain severity score change from baseline to Week 14, analyzed by mixed model repeated measures with multiple imputation.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.60 /

+0.0173 (+2.95%)

TNXP Tonix Pharmaceuticals
$0.60 /

+0.0173 (+2.95%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.60 /

+0.0173 (+2.95%)

  • 16
    Jul
TNXP Tonix Pharmaceuticals
$0.60 /

+0.0173 (+2.95%)

Hot Stocks
Tonix Pharmaceuticals announces results from preclinical study of TNX-1700 » 09:21
06/22/20
06/22
09:21
06/22/20
09:21
TNXP

Tonix Pharmaceuticals

$0.62 /

-0.01 (-1.60%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced that preclinical results of TNX-1700 are being presented in a poster at the American Association of Cancer Research Virtual Annual Meeting II. The meeting is being held online June 22-24, 2020. The poster can be found on the Scientific Presentations page of Tonix's website. A poster, titled "Stabilized recombinant trefoil factor 2 enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer," includes data from a preclinical study which investigated the role of PD-L1 in colorectal tumorigenesis and evaluated the utility of targeting myeloid-derived suppressor cells in combination with PD-1 blockade in mouse models of colorectal cancer. The data show that anti-PD-1 monotherapy was unable to evoke anti-tumor immunity in this model of colorectal cancer, but TFF2-CTP augmented the efficacy of anti-PD-1 therapy. Anti-PD-1 in combination with TFF2-CTP showed greater anti-tumor activity in PD-L1-overexpressing mice. Tonix is developing TNX-1700 (rTFF2-CTP) for the treatment of gastric, colon and pancreatic cancers under a license from Columbia University. The studies conducted were performed by scientists at Columbia University under the direction of Timothy Wang, M.D., Chief of the Division of Digestive and Liver Diseases at Columbia University Irving Medical Center.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.62 /

-0.01 (-1.60%)

TNXP Tonix Pharmaceuticals
$0.62 /

-0.01 (-1.60%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.62 /

-0.01 (-1.60%)

TNXP Tonix Pharmaceuticals
$0.62 /

-0.01 (-1.60%)

Hot Stocks
Tonix Pharmaceuticals, Southern Research expand COVID-19 vaccine collaboration » 07:05
06/18/20
06/18
07:05
06/18/20
07:05
TNXP

Tonix Pharmaceuticals

$0.62 /

-0.0035 (-0.56%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding announced an expansion of its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix's TNX-1800, which is a live replicating virus vaccine designed to protect against COVID-19. The data will support the interpretation of animal trial results with TNX-1800, which are expected in the fourth quarter of 2020 and subsequent human trials. A team of scientists from Southern Research, including Raj Kalkeri, Ph.D., Elizabeth Wonderlich, Ph.D., John Farmer, Ph.D. and Fusataka Koide, Director of Virology, is working on this collaboration.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.62 /

-0.0035 (-0.56%)

TNXP Tonix Pharmaceuticals
$0.62 /

-0.0035 (-0.56%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.62 /

-0.0035 (-0.56%)

TNXP Tonix Pharmaceuticals
$0.62 /

-0.0035 (-0.56%)

Over a month ago
Hot Stocks
Tonix acquires migraine, pain treatment programs of Trigemina » 14:57
06/11/20
06/11
14:57
06/11/20
14:57
TNXP

Tonix Pharmaceuticals

$0.64 /

-0.0198 (-3.02%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding Corp. announced an agreement whereby Tonix will acquire the migraine and pain treatment technologies of Trigemina, and will assume the license for some of the technologies from Stanford University. The lead asset, TNX-1900 is a proprietary, patented enhanced formulation of nasal oxytocin, with demonstrated activity in several non-clinical studies in pain including migraine prophylaxis and neuropsychiatric models and with safety data from non-U.S. studies.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0198 (-3.02%)

TNXP Tonix Pharmaceuticals
$0.64 /

-0.0198 (-3.02%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0198 (-3.02%)

TNXP Tonix Pharmaceuticals
$0.64 /

-0.0198 (-3.02%)

Hot Stocks
Tonix Pharmaceuticals appoints Richard Bagger to board of directors » 07:17
06/10/20
06/10
07:17
06/10/20
07:17
TNXP

Tonix Pharmaceuticals

$0.71 /

-0.0179 (-2.46%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced the appointment of Richard Bagger to its Board of Directors, effective as of June 9, 2020. Mr. Bagger assumes the seat held by John Rhodes, who has stepped down from the position of company director that he has held since 2011. Bagger is a Partner and Executive Director of Christie 55 Solutions, a New Jersey-based consulting firm that provides strategic counsel and consulting services to assist clients with business strategies and opportunities, and with complex public policy and regulatory challenges at the state, federal and international levels.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.71 /

-0.0179 (-2.46%)

TNXP Tonix Pharmaceuticals
$0.71 /

-0.0179 (-2.46%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.71 /

-0.0179 (-2.46%)

TNXP Tonix Pharmaceuticals
$0.71 /

-0.0179 (-2.46%)

Hot Stocks
Tonix selects Fujifilm Diosynth Biotechnologies as manufacturing partner » 07:18
06/01/20
06/01
07:18
06/01/20
07:18
TNXP

Tonix Pharmaceuticals

$0.64 /

-0.0207 (-3.12%)

, FUJIY

Fujifilm

$0.00 /

+ (+0.00%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding Corp. (TNXP) announced an agreement whereby FUJIFILM Diosynth Biotechnologies (FUJIY) will provide contract manufacturing and development services to support the manufacturing of Tonix's COVID-19 vaccine candidate, TNX-1800, for clinical trial supply. Under the agreement, FUJIFILM Diosynth Biotechnologies will develop a manufacturing process, manufacture, and stock a supply of TNX-1800 at FDB's College Station, Texas site for Tonix's clinical development. FDB's manufacturing site in College Station, Texas is a state-of-the-art facility designed to operate as a flexible, responsive contract manufacturing facility to support production on multiple scales as candidates move through the clinical process from clinical stages into commercialization. In February, Tonix announced a strategic collaboration with Southern Research to support the development of TNX-1800 to protect against the new coronavirus disease, COVID-19, based on Tonix's proprietary horsepox vaccine platform. Tonix is developing TNX-801 as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a monkeypox preventing vaccine. The Company believes that its proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0207 (-3.12%)

TNXP Tonix Pharmaceuticals
$0.64 /

-0.0207 (-3.12%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
FUJIY Fujifilm
$0.00 /

+ (+0.00%)

02/24/20 Jefferies
Fujifilm upgraded to Buy from Hold at Jefferies
TNXP Tonix Pharmaceuticals
$0.64 /

-0.0207 (-3.12%)

FUJIY Fujifilm
$0.00 /

+ (+0.00%)

TNXP Tonix Pharmaceuticals
$0.64 /

-0.0207 (-3.12%)

Hot Stocks
Tonix announces results from PK analyses of TNX-102 SL, TNX-601 CR » 07:18
05/21/20
05/21
07:18
05/21/20
07:18
TNXP

Tonix Pharmaceuticals

$0.70 /

+0.0063 (+0.91%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding posted two posters for the American Society of Clinical Psychopharmacology 2020 Annual Meeting to be held online virtually on May 29-30, 2020. The posters can be found on the Scientific Presentations page of Tonix's website. A poster, titled "Pharmacokinetic Results of Dose Proportionality and Food Effect Study of a Sublingual Formulation of Cyclobenzaprine HCl" includes pharmacokinetic analyses of TNX-102 SL that is being developed as a bedtime treatment for fibromyalgia, posttraumatic stress disorder, agitation in Alzheimer's disease and alcohol use disorder. Sixteen healthy subjects, ages 18-65, were randomized in a 3-way crossover to receive a single dose of TNX-102 SL 2.8 mg fasted, TNX-102 SL 5.6 mg fasted, and TNX-102 SL 5.6 mg fed using a standardized high-fat meal. A poster, titled "Phase 1 Pharmacokinetic Study of a Once-Daily Formulation of TNX-601 CR Tablets," includes PK analyses of TNX-601 CR which is being developed as a once-daily treatment of major depressive disorder, PTSD and corticosteroid-induced cognitive dysfunction. In this single-center, open-label, multiple sequential period study, a single cohort of 12 male and female healthy volunteers were administered in successive periods: tianeptine sodium 12.5 mg, tianeptine oxalate 13.1 mg, tianeptine oxalate CR 39.4 mg in a fasted state; and TNX-601 CR in a fed state using a standardized high-fat meal.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$0.70 /

+0.0063 (+0.91%)

TNXP Tonix Pharmaceuticals
$0.70 /

+0.0063 (+0.91%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$0.70 /

+0.0063 (+0.91%)

TNXP Tonix Pharmaceuticals
$0.70 /

+0.0063 (+0.91%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.